{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-061383","form_type":"8-K","ticker":"CSBR","cik":"0000771856","company_name":"CHAMPIONS ONCOLOGY, INC.","filed_at":"2026-09-10T20:46:58+00:00","discovered_at":"2026-09-10T20:48:13.708863+00:00","generated_at":"2026-09-10T20:48:21.242184+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Champions Oncology Q1 revenue up 8.8% to $15.2M; adjusted EBITDA $671K vs $59K","bullets":["Revenue $15.2M, +8.8% YoY; oncology services margin improved to 51% from 43%.","Adjusted EBITDA $671K vs $59K; net loss narrowed to $426K from $466K.","Sales & marketing expense up 66.6% to $3.1M on commercial expansion.","Cash $4.4M, no debt; net cash used in ops ~$492K.","R&D up 12.6% to $2.3M, driven by Corellia share-based compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-061383","json":"https://secwatch.observer/filing/0001628280-26-061383.json","markdown":"https://secwatch.observer/filing/0001628280-26-061383.md","text":"https://secwatch.observer/filing/0001628280-26-061383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/0001628280-26-061383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/771856/000162828026061383/csbr-20260910.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-10T20:48:21.242184+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}